relamorelin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
024620152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND & AIMS Gastroparesis is a complication of diabetes with few treatment options. Relamorelin (also referred to as RM-131… (More)
  • figure 2
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Current treatments for gastroparesis are limited. Chronic idiopathic constipation (CIC) has more treatment options… (More)
Is this relevant?
Review
2017
Review
2017
There is an unmet need for effective pharmacological therapies for constipation, a symptom that significantly deteriorates… (More)
  • table 1
Is this relevant?
2017
2017
BACKGROUND Bowel dysfunction, including both slow transit constipation and defecatory dysfunction, is a frequent and often… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2016
2016
BACKGROUND & AIMS Gastroparesis is an important complication of diabetes. We investigated the effects of relamorelin (a… (More)
  • figure 3
  • table 1
  • table 2
  • table 4
Is this relevant?
2016
2016
BACKGROUND Synthetic human ghrelin accelerates gastric emptying, reduces gastric accommodation, and results in numerical… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2015
2015
BACKGROUND & AIMS Ghrelin receptors are located in the colon. Relamorelin is a pentapeptide selective agonist of ghrelin receptor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
The pentapeptide ghrelin agonist, relamorelin, accelerates colonic transit in patients with chronic constipation (CC). In a… (More)
  • figure 1
  • table 2
  • table 1
  • table 3
  • figure 2
Is this relevant?
2015
2015
The propulsion of colonic contents throughout the large bowel is one of the main mechanisms involved in the act of defecation… (More)
Is this relevant?
Review
2015
Review
2015
BACKGROUND Synthetic ghrelin agonists, predominantly small molecules, are being developed as prokinetic agents that may prove… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?